Business Segment Information

3 Months Ended

Jan. 31, 2019

Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.

Total identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets.

Segment information:



Three Months Ended January 31,
(In millions)	2019			2018
CooperVision net sales by category:
Toric lens	$	146.0		$	137.8
Multifocal lens	49.1			46.9
Single-use sphere lens	132.1			116.3
Non single-use sphere and other	142.9			143.8
Total CooperVision net sales	470.1			444.8
CooperSurgical net sales by category:
Office and surgical procedures	95.7			88.2
Fertility	62.3			57.0
Total CooperSurgical net sales	158.0			145.2
Total net sales	$	628.1		$	590.0
Operating income (loss):
CooperVision	$	116.3		$	112.3
CooperSurgical	7.2			(9.3		)
Corporate	(12.6		)	(12.8		)
Total operating income	110.9			90.2
Interest expense	18.2			18.4
Other income, net	1.1			3.0
Income before income taxes	$	93.8		$	74.8



(In millions)	January 31, 2019		October 31, 2018
Total identifiable assets:
CooperVision	$	3,869.8	$	3,746.0
CooperSurgical	2,214.6		2,201.7
Corporate	214.2		165.1
Total	$	6,298.6	$	6,112.8

Geographic information:



Three Months Ended January 31,
(In millions)	2019		2018
Net sales to unaffiliated customers by country of domicile:
United States	$	278.9	$	261.5
Europe	209.7		203.8
Rest of world	139.5		124.7
Total	$	628.1	$	590.0



(In millions)	January 31, 2019		October 31, 2018
Net property, plant and equipment by country of domicile:
United States	$	550.2	$	516.7
Europe	349.6		340.7
Rest of world	124.0		118.6
Total	$	1,023.8	$	976.0